GILD NASDAQ
Gilead Sciences, Inc.
1W: +3.7%
1M: +5.1%
3M: +18.1%
YTD: +30.5%
1Y: +32.3%
3Y: +118.5%
5Y: +182.7%
$159.08
+0.39 (+0.25%)
After Hours: $158.15 (-0.93, -0.58%)
Weekly Expected Move ±4.0%
$144
$150
$156
$162
$169
Credit Risk of going bust: lower than 84% of companies Debt: 11.8% of company value Bonds: $407.1M held by 325 funds, 58 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.38 (down 99.1%), Gilead Sciences, Inc. would be worth roughly what it owes.
Total debt $26.25B against a stock market value of $196.77B.
Distance to default 10.79 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $14.33B (short-term plus half of long-term), stock volatility 26.8%; Altman Z 3.79. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.38 (down 99.1%), Gilead Sciences, Inc. would be worth roughly what it owes.
Total debt $26.25B against a stock market value of $196.77B.
Distance to default 10.79 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $14.33B (short-term plus half of long-term), stock volatility 26.8%; Altman Z 3.79. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
25 relationships4
As Filer
counterparties named
21
As Counterparty
mentioned by others
2
Rel. Types
2021-11-18
Earliest Filing
2026-02-23
Latest Filing
target: 2
acquirer: 2
Counterparties (Filed by GILD)
4 relationshipsCompanies named in GILD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Arcellx, Inc. | ACLX | target | Target company in the merger agreement to be acquired by Gilead Sciences, Inc. | 2026-02-23 | View |
| Ravens Sub, Inc. | — | acquirer | Wholly owned subsidiary of Gilead Sciences, Inc. acting as the Purchaser in the merger. | 2026-02-23 | View |
| CymaBay Therapeutics, Inc. | — | target | Target company in a merger agreement to be acquired by Gilead Sciences, Inc. | 2024-02-12 | View |
| Pacific Merger Sub, Inc. | — | acquirer | Wholly-owned subsidiary of Gilead Sciences, Inc. acting as the acquirer in the merger. | 2024-02-12 | View |
Mentioned As Counterparty
21 mentionsOther companies that named GILD in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| ACLX Arcellx, Inc. | target | Parent company acquiring Arcellx, Inc. in a two-step merger transaction. | 2026-02-23 | View |
| ASMB ASSEMBLY BIOSCIENCES, INC. | investor | Investor in the private placement of common stock and warrants. | 2025-08-11 | View |
| HOOK HOOKIPA Pharma Inc. | target | Acquired assets related to HB-400 and HB-500 programs from HOOKIPA Pharma Inc. and Hookipa Biotech GmbH. | 2025-05-22 | View |
| ASMB ASSEMBLY BIOSCIENCES, INC. | partner | Partner in an amended option, license, and collaboration agreement involving restructuring of fees and an upfront paymen | 2024-12-19 | View |
| RCUS Arcus Biosciences, Inc. | partner | Holder of an option on certain assets securing the loan. | 2024-08-27 | View |
| ASMB ASSEMBLY BIOSCIENCES, INC. | investor | Purchased 179,500 shares of common stock and warrants in a private placement and amended existing equity agreements. | 2024-06-18 | View |
| AGEN AGENUS INC | partner | Counterparty to an Option and License Agreement covering assets sold to Ligand. | 2024-05-30 | View |
| AGEN AGENUS INC | partner | Original licensor under an Option and License Agreement with Agenus Inc., whose milestone payments were sold to Ligand. | 2024-05-07 | View |
| LGNZZ LIGAND PHARMACEUTICALS INC | partner | Partnered oncology program (AGEN2373) subject to royalty agreement | 2024-05-07 | View |
| XLO Xilio Therapeutics, Inc. | partner | Exclusive global license agreement for XTX301 and equity investment | 2024-03-28 | View |
| RCUS Arcus Biosciences, Inc. | investor | Purchased 15.2M shares in a financing round and appointed a director to the board. | 2024-01-30 | View |
| HOOK HOOKIPA Pharma Inc. | investor | Purchased $21.25 million of common stock and committed to purchase an additional $30.0 million under an amended stock pu | 2023-12-21 | View |
| IDYA IDEAYA Biosciences, Inc. | partner | Clinical study collaboration and supply agreement to evaluate IDE397 and Trodelvy combination in MTAP-deletion bladder c | 2023-12-04 | View |
| ACLX Arcellx, Inc. | investor | Investor purchasing common stock and partner in collaboration agreement | 2023-11-15 | View |
| ASMB ASSEMBLY BIOSCIENCES, INC. | partner | Entered into an Option, License and Collaboration Agreement and equity investment agreements for exclusive licensing of | 2023-10-17 | View |
| RCUS Arcus Biosciences, Inc. | supplier | Gilead agreed to purchase 1,010,000 shares of Arcus common stock at $19.26 per share under an amended stock purchase agr | 2023-06-28 | View |
| RCUS Arcus Biosciences, Inc. | partner | Amendment to Option, License and Collaboration Agreement for inflammatory disease research programs | 2023-05-15 | View |
| MGNX MACROGENICS INC | partner | Exclusive option and collaboration agreement to develop MGD024 and two additional bispecific research programs. | 2022-10-17 | View |
| HOOK HOOKIPA Pharma Inc. | partner | Partner in Amended and Restated Research Collaboration and License Agreement | 2022-03-01 | View |
| HOOK HOOKIPA Pharma Inc. | partner | Partnered with Hookipa Pharma Inc. for a research collaboration and license agreement regarding HIV and HBV programs, in | 2022-02-15 | View |
| RCUS Arcus Biosciences, Inc. | partner | Amendment to Option, License and Collaboration Agreement involving option exercise for three programs and co-development | 2021-11-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-05-20 | Material Agreement; Financial Obligation; Other Events; Exhibits | Agreement | View |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-05-04 | Shareholder Vote; Exhibits | View | |
| 2026-04-28 | Regulation FD; Other Events; Exhibits | View | |
| 2026-02-23 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2026-02-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-19 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-06 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-14 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-04 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-05-08 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-04-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-12 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-02-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-13 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-11-20 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Other Events; Fin | Agreement | View |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR